Gossamer Bio, Inc. (GOSS)
NASDAQ: GOSS · Real-Time Price · USD
2.375
-0.295 (-11.05%)
Feb 4, 2026, 12:53 PM EST - Market open
Gossamer Bio Employees
As of December 31, 2024, Gossamer Bio had 145 total employees, including 144 full-time and 1 part-time employees. The number of employees increased by 10 or 7.41% compared to the previous year.
Employees
145
Change (1Y)
10
Growth (1Y)
7.41%
Revenue / Employee
$303,800
Profits / Employee
-$1,076,972
Market Cap
549.71M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 145 | 10 | 7.41% | 144 | 1 |
| Dec 31, 2023 | 135 | -43 | -24.16% | 135 | 0 |
| Dec 31, 2022 | 178 | -7 | -3.78% | 178 | 0 |
| Dec 31, 2021 | 185 | -11 | -5.61% | 185 | 0 |
| Dec 31, 2020 | 196 | 25 | 14.62% | 195 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| REGENXBIO | 353 |
| ProKidney | 204 |
| Alpha Tau Medical | 125 |
| Keros Therapeutics | 82 |
| Lexeo Therapeutics | 61 |
| Design Therapeutics | 55 |
| Contineum Therapeutics | 41 |
GOSS News
- 26 days ago - Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Gossamer Bio to Participate in Upcoming Investor Conferences - Business Wire
- 3 months ago - Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 4 months ago - Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital - PRNewsWire
- 4 months ago - Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension - Business Wire
- 4 months ago - Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 - Business Wire
- 5 months ago - Gossamer Bio: Bullish Ahead Of Seralutinib's Phase 3 Readout - Seeking Alpha
- 5 months ago - Gossamer Bio to Present at Upcoming Investor Conferences - Business Wire